drugset
Drugs / 2-Aminoethanesulfonic Acid
last change Aug 2019 re-read 2 minutes ago

2-Aminoethanesulfonic Acid

Investigated by
Nanjing Yoko Biomedical Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

today NCT04218513 · Ph 1
2020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04218513 May 2019 — Nanjing Yoko Biomedical Co., Ltd. Completed No outcome recorded
Also used as a comparator or background therapy in 1 trial
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT04219865 Comparator Jun → Aug 2019 — Nanjing Yoko Biomedical Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as 2-Aminoethanesulfonic Acid “Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min” NCT04219865 ↗
1

NCT04218513 ↗
Route Intravenous “Compound Edaravone 30mg-600mg (containing edaravone 30 mg and 2-aminoethanesulfonic acid 600 mg) / placebo single intravenous infusion for 30min” NCT04219865 ↗